Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Medically reviewed by Qin Rao, MD Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, ...

If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...

The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial,” published in ...

A set of chameleon-like immune cells could be contributing to severe asthma in some patients.Intermediate group 2 i ...

In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American ...

Associated allergic diseases (atopic dermatitis or asthma). Family history ... cell-mediated gastrointestinal disorders Eosinophilic esophagitis (EE): symptoms mimicking gastroesophageal reflux ...

Study identifies eosinophil levels as key to predicting gastrointestinal lesions in eosinophilic granulomatosis, offering a ...

Eosinophilic inflammation plays a role in at least half of asthma and one-third of COPD flare-ups. For these people, targeting eosinophils when symptoms worsen is a promising strategy.